Furthermore, although the categories of dermatomyositis are far accurate on the basis of myositis-specific antibodies (MSAs) and other laboratory parameters, heterogeneity remains a significant concern in certain phenotypes, such as concomitant malignant tumors, if any, in dermatomyositis with anti-transcription intermediary factor 1-gamma (TIF1g) antibody (3). This evidence concerns the gene TRIM33 and dermatomyositis.